Avrahan Shkalim
Co-founder & CEO
Claimed by owner CardioSert
Former names:
Advanced Tools for Interventional Cardiologists Performing PCI Procedures
CardioSert
www.apnews.com
•
May 25, 2018
Microbot Medical Closes Acquisition of Novel Technology from CardioSert Ltd.
globenewswire.com
•
Apr 16, 2018
Microbot Medical Exercises Option to Acquire Novel Technology from CardioSert Ltd.
www.knobbe.com
•
Jan 8, 2018
Microbot Medical to Acquire CardioSert's Technology
marketexclusive.com
•
Jan 4, 2018
MICROBOT MEDICAL INC. (NASDAQ:MBOT) Files An 8-K Entry into a Material Definitive Agreement
About
CardioSert develops tools designed to support interventional cardiologists in percutaneous coronary intervention (PCI) procedures. The companys products include a proprietary guide wire designed for crossing complex lesions, such as chronic total occlusion (CTO), and a pressure guide wire for measuring fractional flow reserve (FFR).
CardioSerts CTO tool enables the physician to gently maneuver within the microchannels that pass throughout the arterial blockage. The tool follows the microchannels in order to pass the blockage safely and quickly, allowing the delivery of balloon/stent catheters to the desired location within the blockage.
The companys FFR tool acts as an off-the-shelf workhorse guide wire and is equipped with a means for sensing the level of artery recanalization or assessing the level of artery blockage pre-operation, providing the physician with an important clinical decision-making tool.
CardioSerts CTO tool was licensed by Microbot Medical Inc in 2018. In May 2019, Microbot acquired a novel patent-protected technology from CardioSert and now owns CardioSerts innovative technology, including R&D information, technical know-how, and intellectual property.
CardioSerts CTO tool enables the physician to gently maneuver within the microchannels that pass throughout the arterial blockage. The tool follows the microchannels in order to pass the blockage safely and quickly, allowing the delivery of balloon/stent catheters to the desired location within the blockage.
The companys FFR tool acts as an off-the-shelf workhorse guide wire and is equipped with a means for sensing the level of artery recanalization or assessing the level of artery blockage pre-operation, providing the physician with an important clinical decision-making tool.
CardioSerts CTO tool was licensed by Microbot Medical Inc in 2018. In May 2019, Microbot acquired a novel patent-protected technology from CardioSert and now owns CardioSerts innovative technology, including R&D information, technical know-how, and intellectual property.
Primary Sector
Life Sciences & HealthTech
Products
FFR, CTO
Geographic markets
Global
Funding
Total Funding
Undisclosed
Last Funding
Undisclosed
Funding Stage
Total Rounds
2
Investors
3
News
(4)
www.apnews.com
•
May 25, 2018
Microbot Medical Closes Acquisition of Novel Technology from CardioSert Ltd.
globenewswire.com
•
Apr 16, 2018
Microbot Medical Exercises Option to Acquire Novel Technology from CardioSert Ltd.
www.knobbe.com
•
Jan 8, 2018
Microbot Medical to Acquire CardioSert's Technology
marketexclusive.com
•
Jan 4, 2018
MICROBOT MEDICAL INC. (NASDAQ:MBOT) Files An 8-K Entry into a Material Definitive Agreement
The Team
(2)
AS
NP
Noam Peleg
Co-founder & CTO
Connect with
What is the reason for connecting?
Your company *
Your position *
Add invitation message
0/300
Sending invitation...
Company Lifecycle
Private Equity Funding
Seed
Undisclosed
Jun 2012
1 Investors
Undisclosed
Undisclosed Round
Undisclosed
Jul 2014
2 Investors
Undisclosed
Media gallery
(2)
CardioSert Pen
Locations
Israel
HaShoshanim Street 24, Nesher, Israel
Locations
Israel
HaShoshanim Street 24, Nesher, Israel
Unlock financial data
Finder is provided for free by the non-profit organization Start-Up Nation Central.
- Get unlimited search results
- Save to custom lists - Smartlists
- Get notified with news and updates
- Connect with people
And much more...
I already have access,